ResMed Inc.
NYSE:RMDMedical - Devices
+$1.58 today
- Market cap
- $34.12B
- Beta
- 0.78
- P/E (TTM)
- 18.1
- EPS (TTM)
- $10.37
- Dividend yield
- 1.28%
Volume 1.22M
Average 1.32M
RMD Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
ResMed Inc.NYSE: RMD
Capital Expenditures · Q4 FY2026 · quarter ended Jun 2026
Capital expenditures growth accelerates
Q4 FY2026 capital expenditures of $156.29M (cash outflow) rose 411.0% year over year, ahead of the +188.0% change in trailing-twelve-month capital expenditures. Sequentially, it rose 364.4% from the prior quarter. Over 3 fiscal years it compounded at +5.3% a year.
Context
- Capital expenditures amounted to 2.8% of revenue in FY2026, up 1.0 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2026 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +411.0% holds above the trailing-twelve-month pace of +188.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2026
- (156.29M) USD
- Year-over-year change
- -73.9%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | (156.29M) | -73.9% |
| FY2025 | 2025-06-30 | (89.87M) | +21.8% |
| FY2024 | 2024-06-30 | (114.86M) | +14.3% |
| FY2023 | 2023-06-30 | (134M) | +14.1% |
| FY2022 | 2022-06-30 | (156.04M) | — |
Capital Expenditures vs competitors
How RMD compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +188.0% is the 2nd highest of 9, against a peer median of +12.3%.
- Capital expenditures amounts to 4.7% of revenue for RMD, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $1.9B USD | +3.3% | +9.3% | 5.1% | |
| LTM Jun 2026 | $904M USD | -7.2% | +12.7% | 4.3% | |
| LTM Jun 2026 | $522M USD | +21.4% | +15.8% | 2.6% | |
| LTM Sep 2026 | $491.5M USD | -28.7% | +0.5% | 4.2% | |
| LTM Jun 2026 | €382.2M EUR | +76.2% | -16.8% | 2.2% | |
| LTM Jun 2026 | $267.46M USD | +188.0% | +5.3% | 4.7% | |
| LTM Jun 2026 | $39.98M USD | +23.3% | +61.8% | 4.4% | |
| LTM Jun 2026 | $11.81M USD | -90.0% | +6.3% | 0.5% | |
| LTM Mar 2026 | $304K USD | +284.8% | -41.5% | 0.4% | |
| Peer median (excluding RMD) | — | +12.3% | +7.8% | 3.4% | |
Competitors are the stored peer set for RMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Net Income | 779.44M | 897.56M | 1.02B | 1.4B | 1.52B |
| Depreciation & Amortization | 193.84M | 197.56M | 216.21M | 235.81M | 244.15M |
| Deferred Income Tax | 0 | 216K | 0 | 0 | 0 |
| Stock-Based Compensation | 65.26M | 71.14M | 80.18M | 91.66M | 104.35M |
| Change in Working Capital | (708.08M) | (462.13M) | 44.78M | 16.74M | (74.24M) |
| Accounts Receivables | 19.35M | (106.51M) | (134.28M) | (76.68M) | (96.78M) |
| Inventory | (311.68M) | (248.83M) | 172.2M | (80.17M) | (9.92M) |
| Accounts Payables | (247.63M) | 31.34M | 0 | 90.96M | 172.72M |
| Other Working Capital | (168.11M) | (138.13M) | 6.86M | 82.63M | (140.26M) |
| Other Non-Cash Items | 20.69M | (11.05M) | 39.13M | 6.66M | 8.28M |
| Operating Cash Flow | 351.15M | 693.3M | 1.4B | 1.75B | 1.81B |
| Capital Expenditures | (156.04M) | (134M) | (114.86M) | (89.87M) | (156.29M) |
| Acquisitions (Net) | (42.78M) | (1.01B) | (133.46M) | (139.25M) | (350.72M) |
| Purchases of Investments | (20.72M) | (32.23M) | (22.46M) | (6.42M) | (28.54M) |
| Sales of Investments | 6.8M | 3.94M | 1M | 0 | 2.75M |
| Other Investing Activities | (17.18M) | 15.2M | (15.4M) | 35.48M | (12.41M) |
| Investing Cash Flow | (229.92M) | (1.16B) | (269.78M) | (200.05M) | (545.2M) |
| Debt Repayment | 122M | 665M | (730M) | (40M) | (10M) |
| Common Stock Issued | 47.38M | 49.14M | 53.09M | 74.44M | 74.5M |
| Common Stock Repurchased | 0 | 0 | (150.01M) | (300.03M) | (700.04M) |
| Dividends Paid | (245.34M) | (258.28M) | (282.32M) | (310.88M) | (349.66M) |
| Other Financing Activities | (52.41M) | (32.99M) | (10.05M) | (29.79M) | (21.83M) |
| Financing Cash Flow | (128.36M) | 422.87M | (1.12B) | (606.25M) | (1.01B) |
| Effect of Forex Changes | (14.43M) | (2.15M) | (1.72M) | 25.8M | 6.18M |
| Net Change in Cash | (21.57M) | (45.82M) | 10.47M | 971.09M | 259.78M |
| Free Cash Flow | 195.11M | 559.3M | 1.29B | 1.66B | 1.65B |
ResMed Inc.
NYSE:RMD
Intrinsic Alpha fair value
Locked
Current Price
$242.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.